
|Videos|May 18, 2020
Supplements and Featured Publications
- Therapeutic Changes in HER2+ Breast Cancer
- Volume 1
- Issue 1
Novel Treatments in HER2-Positive Breast Cancer
OncLive interviewed experts on novel treatments in HER2-positive breast cancer.
Advertisement
OncLive interviewed experts on novel treatments in HER2-positive breast cancer.
Supported by an unrestricted educational grant by Daiichi Sankyo
Articles in this issue
almost 6 years ago
Dr. Thompson on Sequencing Strategies in HER2+ Breast Canceralmost 6 years ago
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5


































